RxDoctor Payments Data

Antoine Dakouny, MD

Internal Medicine · Port Charlotte, FLNPI 1538232384

Payments from drug & device makers

$113in general payments, 2019–2025

Across 7 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$34
  • Novo Nordisk$22
  • Amgen$17
  • Merck$16
  • Lilly USA, LLC$12
  • AstraZeneca$11

What the payments were for

  • Food & beverage$10190%
  • Education$1210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK2$34
Novo Nordisk1$22
Amgen1$17
Merck1$16
Lilly USA, LLC1$12
AstraZeneca1$11

How this compares

$113 in reported general payments places this provider in the 25th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$386,849
Medicare patients
661
Services billed
3,458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban195$204,146
OzempicSemaglutide164$196,253
TrulicityDulaglutide104$147,629
MounjaroTirzepatide45$58,743
XareltoRivaroxaban45$58,628
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$58,623
NayzilamMidazolam21$40,947
MyrbetriqMirabegron43$35,240
JardianceEmpagliflozin18$30,292
JanuviaSitagliptin Phosphate13$23,070
Tresiba Flextouch U-100Insulin Degludec20$22,759
LinzessLinaclotide20$17,367
Breo ElliptaFluticasone/Vilanterol33$16,249
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$9,320
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$8,900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$12$206,372149 claims
Novo NordiskOzempic$22$196,253164 claims
GSKTrelegy Ellipta, Breo Ellipta$34$74,87181 claims
MerckJanuvia$16$23,07013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Port Charlotte

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →